Akari Therapeutics Plc (AKTX) Q3 2024 Earnings Report

Akari Therapeutics reported its QQ3 2024 results with no revenue, continuing a burn-driven cash outflow characteristic of a clinical-stage biotech. For the quarter ended September 30, 2024, R&D expenditures were modest at $0.143 million, while G&A and SG&A costs dominated operating expense at $1.709 million each, culminating in an operating loss of $2.927 million and a net loss of $2.895 million ($0.20 per fully diluted share). Cash and cash equivalents stood at $2.246 million at quarter-end, down from $4.177 million at the start of the period, with net cash used in operating activities of $1.49 million and a net cash decrease of $1.931 million for the quarter. The balance sheet shows total liabilities of $9.428 million versus total assets of $2.734 million, yielding negative stockholders’ equity of $6.694 million, underscoring a liquidity challenge typical of earlier-stage biotech companies awaiting pivotal clinical milestones or funding events.

Q3 2024 saw a meaningful sequential reduction in operating expenses relative to Q2 2024, suggesting ongoing cost-control efforts. However, the lack of revenue and the need for external funding remain the central investment risk. The company’s prospects hinge on the nomacopan program and any upcoming clinical data readouts or strategic partnerships that could extend the company’s runway and unlock value. Management commentary is not available in the provided data, limiting the ability to quote direct guidance or sentiment from leadership. Investors should watch for clinical milestones, potential licensing discussions, and any additional financing transactions that could alter the liquidity profile and capital structure.